Zydus Cadila Gets Approval from USFDA to Market Anti- Depressant Drug

Shital Jibhe / 05 Jun 2017

Zydus Cadila Gets Approval from USFDA to Market Anti- Depressant Drug

The USFDA has given its final approval to Zydus Cadila to market Mirtazapine Orally Disintegrating Tablets USP in strengths of 15 mg, 20mg, and 45mg, said Cadila Healthcare in a BSE filing on Monday.

The USFDA has given its final approval to Zydus Cadila to market Mirtazapine Orally Disintegrating Tablets USP in strengths of 15 mg, 20mg, and 45mg, said Cadila Healthcare in a BSE filing on Monday.
 
The drug is an anti-depressant and will be produced at the group’s formulations manufacturing facility at Baddi.
 
The group has so far filed over 300 ANDAs and now has more than 115 approvals, since the commencement of the filing process in FY 2003-04, it added.
 
Trading at Rs 497, Cadila Healthcare Limited was up by Rs 2.45 or 0.50% as at 10.17 on Monday, on the BSE. The stock had hit a high of Rs 500.

If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.